MDxHealth S.A. (MDXH)
MDxHealth S.A. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Herstal, WA, BE. The stock last traded at $0.46, up 3.92% on the session, giving a market capitalisation of $23.5M. On trailing twelve-month figures it carries a trailing P/E of -0.68, a net margin of -32.2%. Its beta of 0.38 implies it has historically moved less than the broad market.
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
MDxHealth S.A. is most often compared with the following Healthcare names: